| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/10/2005 | US6890516 Identifying a substance capable of affecting long term memory in an animal comprising the determination that said substance alters activator homodimer, activator-repressor heterodimer and/ or repressor homodimer formation from normal |
| 05/10/2005 | US6890457 Infrared radiation emitting ceramic powders comprising zirconium or radium and oxides of silicon, aluminum, iron, titanium, calcium, magnesium, potassium and sodium, used for joining wood, paper, leather, metals or plastics; radiotherapy |
| 05/10/2005 | CA2407562C Tryptophan source from plants and uses therefor |
| 05/10/2005 | CA2320474C 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines |
| 05/10/2005 | CA2191815C Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation and their use |
| 05/10/2005 | CA2166332C Antiglucocorticoid steroids for the treatment of anxiety disorders |
| 05/10/2005 | CA2153856C Duloxetine enteric pellets |
| 05/10/2005 | CA2067330C Herpes simplex virus type 1 mutant |
| 05/06/2005 | WO2005040835A2 Method for determining the antiradical defense potential and use thereof, in particular in veterinary and human preventive therapeutics |
| 05/06/2005 | WO2005040138A1 Substituted benzylaminoalkylene heterocycles |
| 05/06/2005 | WO2005040121A2 Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| 05/06/2005 | WO2005040108A1 Prolinamide derivatives as sodium and/or calcium channel blockers or selective mao-b inhibitors |
| 05/06/2005 | WO2005039607A1 The use of balloonfish collagen i extractive in medical care and the preparative method of it |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039577A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain |
| 05/06/2005 | WO2005039576A1 Combinations of potassium channel openers and sodium channel inhibitors or active substances influencing sodium channels in order to treat painful conditions |
| 05/06/2005 | WO2005020904A3 Oral neurotherapeutic cefazolin compositions |
| 05/06/2005 | WO2005011711A3 Inhalable gaseous medicine based on xenon and nitrous oxide |
| 05/06/2005 | WO2005000288A3 Treatment of protein aggregation disorders |
| 05/06/2005 | WO2004113568A3 Methods for the diagnosis and prognosis of alzheimer's disease |
| 05/06/2005 | WO2004092116A8 Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof |
| 05/06/2005 | WO2004080419A3 Humanized antibodies that recognize beta amyloid peptide |
| 05/06/2005 | WO2004078180A3 Naaladase inhibitors for treating opioid tolerance |
| 05/06/2005 | WO2004071529A3 Uses of anti-insulin-like growth factor i receptor antibodies |
| 05/06/2005 | WO2004047727A3 Compositions and methods for diagnosing and treating mood disorders |
| 05/06/2005 | WO2003068746A8 Aryl ureas as kinase inhibitors |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | CA2543404A1 Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
| 05/06/2005 | CA2543287A1 Benzazepine derivatives as mao-b inhibitors |
| 05/06/2005 | CA2543189A1 In vivo gene therapy of parkinson's disease |
| 05/06/2005 | CA2542695A1 Substituted benzylaminoalkylene heterocycles |
| 05/06/2005 | CA2542533A1 Method for determining the antiradical defense potential and use thereof, in particular in veterinary and human preventive therapeutics |
| 05/06/2005 | CA2542434A1 Combination of flupirtine and tolperisone or eperisone for the treatment of painful conditions |
| 05/06/2005 | CA2542419A1 Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia |
| 05/06/2005 | CA2541894A1 Amino alcohol derivative, medicinal composition containing the same, and use of these |
| 05/06/2005 | CA2541472A1 Dihydrobenzofuranyl alkanamines and methods for using same as cns agents |
| 05/06/2005 | CA2540022A1 A polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline |
| 05/06/2005 | CA2539967A1 Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| 05/06/2005 | CA2537224A1 Heterocycle-substituted pteridine derivatives and their use in therapy |
| 05/05/2005 | US20050096479 Novel succinate salt of O-desmethyl-venlafaxine |
| 05/05/2005 | US20050096469 Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096460 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same |
| 05/05/2005 | US20050096457 Peptide substrates and fusion polypeptide substrates comprising a beta -secretase cleavage site wherein a human Aspartyl protease cleaves the peptide between P1 and P1, the rate of which cleavage is used to identify modulators of Alzeimer's disease, neurofibrillary tangles, gliosis and neuronal loss |
| 05/05/2005 | US20050096395 Norepinephrine-serotonin reuptake inhibitor (NSRI) compound to treat attention deficit/hyperactivity disorder and Tic disorder; NSRI compound has a NE:5-HT reuptake inhibition ratio of between 1:1 and 10:; milnacipran |
| 05/05/2005 | US20050096382 Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof |
| 05/05/2005 | US20050096377 Substituted sulfonamide-indoles |
| 05/05/2005 | US20050096363 Activator of peroxisome proliferator-activated receptor delta |
| 05/05/2005 | US20050096359 melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride |
| 05/05/2005 | US20050096342 Neurodegenerative disorders |
| 05/05/2005 | US20050096335 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 05/05/2005 | US20050096330 N-(indolecarbonyl) piperazine derivatives |
| 05/05/2005 | US20050096326 4-(4-methylpiperazin-1-yl)4V-(4-morpholinophenyl)-indan-2-carboxamide; h5-HT1B receptor antagonist; serotonin-mediated disorders; oral bioavailability |
| 05/05/2005 | US20050096321 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates |
| 05/05/2005 | US20050096320 potent inhibitors of cyclic guanosine 3',5'-monophosphate-metabolizing phosphodiesterases (cGMP-PDEs)/phosphodiesterase isoenzymes PDE-I, PDE-II, PDE-V; therapeutic, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilatory, natriuretic and diuretic effects; erectile dysfunction |
| 05/05/2005 | US20050096317 Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives |
| 05/05/2005 | US20050096316 Quinoline derivatives(2) |
| 05/05/2005 | US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic |
| 05/05/2005 | US20050096312 Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders |
| 05/05/2005 | US20050096310 Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine |
| 05/05/2005 | US20050096293 Analogs of nitrobenzylthioinosine |
| 05/05/2005 | US20050096279 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 05/05/2005 | US20050096271 Fusion of polypeptides and immunoglobulin protein; immunotherapy ; antiallergens; antiarthritic agents; anticancer agents; antiinflammatory agents |
| 05/05/2005 | US20050096256 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 05/05/2005 | US20050096253 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 05/05/2005 | US20050095703 Generating progenitor cells for use in prevention and treatment of cell proliferative, neurodegenerative and pancreatic disorders; regenerative medicine; tissue engineering |
| 05/05/2005 | US20050095701 Transplanting conditionally-immortalized dorsal root ganglion progenitor cells into mammal to generate peripheral nervous system (PNS) for treatment and prevention of nervous system disorders |
| 05/05/2005 | US20050095650 screening for an agent that modulates capsaicin receptor function |
| 05/05/2005 | US20050095291 Tamper-resistant oral opioid agonist formulations |
| 05/05/2005 | US20050095248 Use of inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence |
| 05/05/2005 | US20050095239 Methods and compositions for treating Alzheimer's disease |
| 05/04/2005 | EP1528058A1 Polymorphic crystalline forms of celecoxib |
| 05/04/2005 | EP1527778A1 Methods of enhancing opiate analgesic potency or detoxifying an opiate addict |
| 05/04/2005 | EP1527775A1 Controlled release formulation containing tramadol |
| 05/04/2005 | EP1527773A1 Pharmaceutical composition comprising sumatriptan |
| 05/04/2005 | EP1527171A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/04/2005 | EP1527077A2 Pyrrolopyrazines as kinase inhibitors |
| 05/04/2005 | EP1527075A1 Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands |
| 05/04/2005 | EP1527074A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/04/2005 | EP1527073A1 Benzothiophene urea, benzofurane urea, and indole urea, and use of the same as alpha-7 achr agonists |
| 05/04/2005 | EP1527070A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| 05/04/2005 | EP1527068A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 05/04/2005 | EP1527062A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 05/04/2005 | EP1527051A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 05/04/2005 | EP1527048A2 N- phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy |
| 05/04/2005 | EP1527046A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 05/04/2005 | EP1526895A2 Methods for treating carbonic anhydrase mediated disorders |
| 05/04/2005 | EP1526869A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 05/04/2005 | EP1526868A2 Antibodies |
| 05/04/2005 | EP1526860A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 05/04/2005 | EP1526852A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/04/2005 | EP1526850A2 Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same |
| 05/04/2005 | EP1526847A2 Pharmaceutical dosage form comprising a sulfite compound |
| 05/04/2005 | EP1526846A2 Gelatin capsule exhibiting reduced cross-linking |
| 05/04/2005 | EP1526845A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 05/04/2005 | EP1526844A2 Pellicle-resistant gelatin capsule |
| 05/04/2005 | EP1526843A1 Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
| 05/04/2005 | EP1448553B1 N-heterocyclyl hydrazides as neurotrophic agents |
| 05/04/2005 | EP1446399B1 Piperazine derivatives having sst1 antagonistic activity |
| 05/04/2005 | EP1424973A4 Disposal system for transdermal dosage form |